Desktop Site
|
19 Apr 24 | 16:00
|
Close
Equity
SME
Eq Drv
Currency
Commodity
Corporates
Get Quote
*
Notices
|
S&P
BSE SENSEX
73,088.33
+599.34
+0.83 %
Corporate Announcement
Security Code
524804
Company
Aurobindo Pharma Ltd
Exchange Received Time
18/05/2022 12:24:11
Exchange Disseminated Time
18/05/2022 12:24:11
Time Taken
00:00:00
Unit 5 - US FDA Inspection - Reg., |
5/18/2022 12:24:11 PM
Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we submit the following: As already informed in the earnings call in Feb 22, the Pre-approval inspection was carried out during the period 8th Feb '22 to 15th Feb '22. On completion of the inspection, Form 483 was issued with 5 observations. Based on the inspection review and the written responses provided by the Company, the Agency has concluded that the assessment is completed with 'no remaining deficiencies'. A copy of the EIR has been received dated 17th May 2022.
Attachment
<< Back
Recently Viewed